Sequence Variants of Peroxisome Proliferator-Activated Receptor-Gamma Gene and the Clinical Courses of Patients with End-Stage Renal Disease. (15th February 2015)

• Record Type: Journal Article
• Authors: Chao, Chia-Ter; Chen, Yen-Ching; Chiang, Chih-Kang; Huang, Jenq-Wen; Hu, Fu-Chang; Fang, Cheng-Chung; Chang, Chen-Chih; Yen, Chung-Jen
• Other Names: Rennert Gad Academic Editor.
• Is Part Of: Disease markers. Volume 2015(2015)
• Publication Date: 2015-02-15
• Subjects: Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.1155/2015/763459
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : Background. PPAR- γ single nucleotide polymorphisms (SNPs) reportedly play an important role in determining metabolic risk among diverse population. Whether PPAR- γ SNPs affect the clinical courses in ESRD patients is unknown. Methods. From a multicenter cohort, we identified 698 patients with prevalent ESRD between 2002 and 2003, and other 782 healthy subjects as control. Two PPAR- γ SNPs, Pro12Ala (rs1801282) and C161T (rs3856806), were genotyped and their association with ESRD was examined. Both groups were prospectively followed until 2007, and the predictability of genotypes for the long-term survival of ESRD patients was analyzed. Results. After multivariable-adjusted regression, GG genotype of Pro12Ala was significantly more likely to associate with ESRD (P < 0.001 ) among patients with non-diabetes-related ESRD. Cox's proportional hazard regression showed that both Pro12Ala and C161T polymorphisms were significant predictors of mortality in ESRD patients with DM (Pro12Ala: GG versus other genotypes, hazard ratio [HR] <0.01;P < 0.001 ; for C161T, CC versus TT genotypes, HR 2.86;P < 0.001 ; CT versus TT genotypes, HR 1.93;P < 0.001 ). Conclusion. This is the first and largest study to evaluate PPAR- γ SNPs in ESRD patients. Further mechanistic study is needed to elucidate the role of PPAR- γ among ESRD patients.